Gelonghui, May 20, 丨 Kangtai Biotech (300601.SZ) announced that the company recently received an acceptance notice issued by the State Drug Administration, agreeing to accept clinical trial applications for the quadrivalent influenza virus lysis vaccine developed by the company in people aged 6-35 months.
The company's quadrivalent influenza virus lysis vaccine (for people aged 3 years and above) is currently in phase I and III clinical trials. The current clinical trial application for the company's quadrivalent influenza virus lysis vaccine for people aged 6-35 months has been accepted. The quadrivalent influenza virus lysis vaccine stimulates the body to develop immunity against the influenza virus and is used to prevent influenza caused by vaccine-related influenza viruses. Influenza (also known as influenza) is an acute respiratory infectious disease caused by the influenza virus. Vaccination against influenza is the most effective and economical measure to prevent influenza disease and influenza outbreaks.
Currently, domestic manufacturers of quadrivalent influenza virus lysis vaccines for people aged 6-35 months include Hualan Biovaccine Co., Ltd., Shanghai Biological Products Research Institute Co., Ltd., and Shenzhen Sanofi Pasteur Biological Products Co., Ltd.